Clinical & Translational Oncology最新文献

{"title":"Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials.","authors":"Bilal Abu-Hussein, Amr Elrosasy, Haidy Samy, Ahmed Said Ali, Said Samir Alijla, Ahmad Naoras Bitar, Ibrahim Gamal","doi":"10.1007/s12094-025-03847-8","DOIUrl":"10.1007/s12094-025-03847-8","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a leading cause of morbidity and mortality among women worldwide. According to the recent statistics by World Health Organization (WHO), it is the leading cause of death from cancer in women worldwide and it is the most frequently diagnosed cancer. This meta-analysis aims to systematically evaluate the efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.</p><p><strong>Method: </strong>We searched five databases; PubMed, Scopus, Science Direct, Web of Science, and Medline Plus. We included six studies. The applicable outcomes for meta-analysis about efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.</p><p><strong>Results: </strong>Six RCTs included in our meta-analysis found that Esketamine group had a statistically significant lower VAS score after 4 h, after 6 h, after 24 h, after 48 h; (MD = -1.54; 95% CI [-1.65, -1.42], P < 0.00001), (MD = -0.55; 95% CI [-0.66, -0.45], P < 0.00001), (MD = -0.75; 95% CI [-0.84, -0.66], P < 0.00001,), (MD = -0.26; 95% CI [-0.48, -0.03], P = 0.03) P < 0.00001), respectively.</p><p><strong>Conclusion: </strong>We conclude that S-ketamine is valuable for reducing pain and safe in patients undergoing modified radical mastectomy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3325-3339"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USP14 targets FABP5-mediated ferroptosis to promote proliferation and cisplatin resistance of HNSCC.","authors":"Jiaxin Qian, Zitong Zhao, Liying Ma, Wensheng Liu, Yongmei Song","doi":"10.1007/s12094-025-03857-6","DOIUrl":"10.1007/s12094-025-03857-6","url":null,"abstract":"<p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) ranks among the most lethal solid tumors in humans, with a five-year survival rate hovering around 50%. The limited understanding of its biological foundation has hindered the development of efficacious targeted therapeutics.</p><p><strong>Methods: </strong>TCGA database and immunohistochemistry were deployed to confirm the expression levels of ubiquitin specific protease 14 (USP14). CCK8 method was used to evaluate the influence of USP14 on cisplatin resistance. Further investigations into the role of USP14 were conducted through assessments of cell proliferation, colony formation, and Transwell assays. The impact of USP14 expression on ferroptosis was evaluated by measuring GSH/GSSG ratios, Fe²⁺ concentrations, and lipid peroxide levels. Co-IP was employed to verify the interaction between USP14 and FABP5.</p><p><strong>Results: </strong>Our analysis revealed that USP14 ranked among the most prominently upregulated deubiquitinases (DUBs) in tissue samples of HNSCC. Notably, aberrant USP14 expression was linked to tumorigenesis and the malignant evolution of HNSCC and further suggested a poor prognosis. In vitro experiment revealed that USP14 depletion markedly inhibited cell growth, cisplatin resistance, invasion and migration capabilities of HNSCC cells. Mechanically, USP14 inhibits FABP5 ubiquitination and degradation, thus positively modulating FABP5 expression. Subsequent analyses demonstrated that the loss of USP14 promoted ferroptosis in HNSCC cells. Finally, in vivo xenograft experiments confirmed that the USP14 small molecular antagonist IU1 could effectively attenuate cisplatin resistance in HNSCC.</p><p><strong>Conclusion: </strong>The results indicate that the USP14-FABP5 axis exerts oncogenic effects on HNSCC, providing a potential target for diagnosing and treating this type of malignancy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3485-3500"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a novel hypermethylation marker, ZSCAN18, and construction of a diagnostic model in cervical cancer.","authors":"Jinhao Yang, Shuang Chen, Yuqing Liu, Ping Wang, Jing Zhao, Jianying Yi, Jin Wei, Rong Wang","doi":"10.1007/s12094-025-03864-7","DOIUrl":"10.1007/s12094-025-03864-7","url":null,"abstract":"<p><strong>Purpose: </strong>Cervical cancer (CC), a common female malignancy, has been linked to alterations in DNA methylation. This study employed an integrated \"dry-wet lab\" strategy combining bioinformatics, machine learning, and experimental validation to identify novel methylation biomarkers for CC.</p><p><strong>Methods: </strong>Methylome and transcriptome data from the TCGA and GEO cohorts (n=349 discovery, n=414 validation) were analyzed to identify differentially methylated CpGs. The top candidates were validated by pyrosequencing, methylation-specific PCR, and quantitative assays. Diagnostic models were developed, and functional studies were performed for the target markers.</p><p><strong>Results: </strong>Eighteen differentially methylated CpGs were identified, with five top candidates (three in the ZSCAN18 promoter) showing diagnostic potential. ZSCAN18 promoter methylation levels and positivity rates were significantly greater in CC tissues than in normal tissues (p<0.05), reaching 77.8% (21/27) in ThinPrep cytology test (TCT) samples. The ridge regression diagnostic model achieved an AUC of 0.9421 in the validation cohort. Similarly, ZSCAN18 overexpression suppressed CC cell proliferation (p<0.05).</p><p><strong>Conclusions: </strong>This study established a rapid, effective and systematic systemic research strategy to screen novel methylation markers for CC. ZSCAN18 promoter methylation correlates with cervical lesion severity, and the diagnostic model enhances the diagnostic ability. These findings highlight the dual role of ZSCAN18 as a diagnostic marker and potential therapeutic target.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3346-3363"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV-driven cancer: from epidemiology to the HPV-driven tumor board proposal, everything you wanted to know but were afraid to ask.","authors":"Daniela Alterio, Michał Gola, Mattia Zaffaroni, Maria Giulia Vincini, Carlo Guglielmo Cattaneo, Cynthia Aristei, Gabriella Macchia, Vitaliana De Sanctis, Francesca DeFelice","doi":"10.1007/s12094-025-03868-3","DOIUrl":"10.1007/s12094-025-03868-3","url":null,"abstract":"<p><strong>Background: </strong>Human papilloma virus (HPV)-related cancers are well-known clinical entities in different body sites. Cervix, anus, and oropharynx are the most common tumors related to the virus infection. The aim of this work was to highlight similarities and differences among HPV-related cancers of different subsites.</p><p><strong>Methods: </strong>The narrative review was focused on the following topics: (1) epidemiology, (2) prognostic factors, (3) treatment approaches, (4) radiomic analysis, (5) radiosensitivity, (6) de-escalation strategies. Common aspects as well as differences have been highlighted for cervical, anal and oropharyngeal HPV-related tumors.</p><p><strong>Results: </strong>Common prognosticators in terms of patients characteristics (anemia, smoking habits), tumor histology (lymph node extracapsular extension) biological features (high circuating HPV DNA), blood cell immunomodulating response (high level of tumor-infiltrating lymphocytes and high neutrophil-to-lymphocyte ratio) as good parameters of radiosensitivity (radiosensitivity index RSI, and genomic adjusted radiation dose GARD) have been found among the analyzed tumor subsites. On the contrary, other aspects like treatment approaches (different RT techniques and doses), radiomic analysis and de-intensification strategies were found to be different among tumors.</p><p><strong>Conclusion: </strong>HPV-related tumors have several common prognostic and predictive features that do not translate into common therapeutic approaches and de-intensification strategies. A better understanding of which factors are associated with a high risk of early recurrence or favourble clinical outcomes could help in guiding clinical assessment and screening activities and might improve efforts for precision medicine.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3511-3529"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2- breast cancer.","authors":"João Queirós Coelho, Beatriz Lau, Rita Pichel, Laura Guerra, Hugo Miranda, Raquel Romão, Maria João Sousa, Fernando Gonçalves, Joana Simões, Sérgio Xavier Azevedo, António Araújo","doi":"10.1007/s12094-025-03856-7","DOIUrl":"10.1007/s12094-025-03856-7","url":null,"abstract":"<p><strong>Introduction: </strong>Neoadjuvant chemotherapy (NACT) is a treatment option for early-stage hormone receptor-positive human epidermal growth factor receptor 2-negative (HR + /HER2-) breast cancer. Despite its use, pathological response rates in this subtype are often lower, and the impact of individual risk factors remains unclear. This study aimed to identify biomarkers and create a predictive score for NACT response.</p><p><strong>Methods: </strong>This retrospective, single-center study included patients with stage IIA-IIIC HR + /HER2- breast cancer treated with NACT and surgery (2019-2023). Multiple logistic regression analyzed associations between clinicopathological variables and pathologic response (partial/complete vs. absent) (p < 0.05). The best-performing model was used to develop a risk score.</p><p><strong>Results: </strong>The study included 101 patients. Significant predictors of pathological response included tumor grade (G2/3 vs. G1), menopausal status (pre- vs. post-menopausal), and intrinsic subtype (luminal B vs. A).</p><p><strong>Conclusions: </strong>A dynamic calculator was created incorporating grade, hormonal status, intrinsic subtype, and Ki-67. This tool provides real-time input, facilitating personalized therapeutic decision-making.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3530-3534"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis.","authors":"Izael Pereira da Silva, Lucas Guimarães Campos Roriz de Amorim, Gabriel Vieira Piredda, Marcelo Mass-Lindenbaum, Francisco Cezar Aquino de Moraes, Pedro F S Freitas, Bárbara Vieira Lima Aguiar Melão, Helisandro Montenegro Brandão, Karine Martins da Trindade","doi":"10.1007/s12094-025-03851-y","DOIUrl":"10.1007/s12094-025-03851-y","url":null,"abstract":"<p><strong>Purpose: </strong>Treatment for metastatic castration-resistant prostate cancer (mCRPC) includes chemotherapy and inhibition of the androgen receptor pathway. However, the optimal treatment sequence in this scenario is not yet fully understood. Therefore, we conducted a systematic review and meta-analysis comparing cabazitaxel versus abiraterone or enzalutamide for efficacy and safety outcomes as second-line therapy in mCRPC patients after docetaxel failure.</p><p><strong>Methods: </strong>We searched PubMed, Embase, and Cochrane databases for interventional studies comparing cabazitaxel versus abiraterone or enzalutamide for patients with mCRPC who have experienced treatment failure with docetaxel as their first-line therapy. We computed hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Eight studies, comprising 1,897 patients were included, of whom 548 (28.8%) received cabazitaxel. Mean follow-up time ranged from 3 to 16.4 months. Median age ranged from 68.1 to 73.9 years in the cabazitaxel group, and 68.0 to 73.1 years in the abiraterone or enzalutamide group. In our meta-analysis, cabazitaxel significantly improved progression-free survival (PFS) rates (HR 0.60; 95% CI 0.47-0.78; p < 0.001) compared to abiraterone or enzalutamide. There were no differences between groups in overall survival (HR 0.76; 95% CI 0.46-1.24; p = 0.27), therapy-related grade ≥ 3 adverse events (AEs) (OR 3.00; 95% CI 0.72-12.40; p = 0.12), and PSA decline ≥ 50% (OR 1.20; 95% CI 0.51-2.80; p = 0.67).</p><p><strong>Conclusions: </strong>In this systematic review and meta-analysis of men with mCRPC after docetaxel failure, second-line therapy with cabazitaxel was associated with a longer PFS compared with abiraterone or enzalutamide, though without a significant difference in OS.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3465-3476"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse large B-cell lymphoma: examining evolving patterns in mortality, incidence, and demographics.","authors":"Silpa Choday, Eric Tran, Miguel Gonzalez","doi":"10.1007/s12094-025-03859-4","DOIUrl":"10.1007/s12094-025-03859-4","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and heterogeneity. This study analyzes recent trends in DLBCL including trends in hospitalization, inpatient mortality, and costs.</p><p><strong>Methods: </strong>Using the Nationwide Inpatient Sample (NIS) database from 2016 until 2020, a retrospective cohort study was performed to identify DLBCL hospitalization, discharges, and investigate outcomes. Trends were adjusted for age, sex, race, insurance type, mean household income, and hospital characteristics. Multivariable logistic regression has been used to analyze the data.</p><p><strong>Results: </strong>A total of 103,588,729 records were analyzed, identifying 47,425 cases with a diagnosis of DLBCL. From 2016 to 2020, hospitalizations have increased from 14,980 to 16,565. The mean age at diagnosis was 65 (P < 0.001). Males were slightly more affected than females (57.3 vs 42.6), with an increasing trend in males from 53.7% to 62.3% (P = 0.03). The highest prevalence was observed in the White population, followed by Hispanics and African Americans. Notably, the prevalence among Hispanics increased from 10 to 12%, while there is a decreasing trend in other demographics (P = 0.05). Medicare was the most common insurance, with increasing trends, followed by Medicaid and private insurance (P = 0.6). Inpatient mortality increased from 6.1 to 7.1 (2016 to 2018) and decreased to 6.1% (2018 to 2020) (P < 0.001). The mean length of the stay remained stable at 11.8 days. However, hospital charges increased from $176,131 to $212,324. Comorbidities such as obesity, hypertension, other associated lymphomas, peripheral vascular diseases, and diabetes showed an increasing trend (P < 0.05). Discharges to home and skilled nursing facility (SNF) decreased, while there was an increase in discharges to home with home health (HH) care and short-term care (P < 0.001).</p><p><strong>Conclusion: </strong>Risk factors for DLBCL include white male sex, with the mean age of 65 years. The incidence among the Hispanic population has been increasing over the years. There are disparities in incidence and survival among different ethnic/demographic groups that need to be addressed by identifying targeted interventions and equitable healthcare access.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3432-3438"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.","authors":"Louis Boafo Kwantwi, James Danquah Boafo, Bevelyn Emefa Egleh, Mingfeng Li","doi":"10.1007/s12094-025-03874-5","DOIUrl":"10.1007/s12094-025-03874-5","url":null,"abstract":"<p><p>Increasing knowledge of the immunosuppressive tumor microenvironment in cancer-related processes has led to the developing of novel immune-based therapies that have changed the cancer treatment paradigm. In the tumor microenvironment, the plethora of soluble factors secreted by tumor cells interacts with immune cells and non-immune components to deliver signals necessary for tumor progression. Accordingly, targeting tumor-derived factors inducing this immunosuppressive tumor microenvironment has become an appealing therapeutic potential in advancing cancer treatment. CCL20, a chemokine best known to induce leucocyte migration in response to pathological and inflammatory conditions, has been implicated in tumor proliferation, angiogenesis, metastasis, immunosuppression, and therapeutic resistance. Notably, CCL20 and its receptor CCR6 are important in tumor microenvironment interactions. This review discusses the interaction between the CCL20-CCR6 axis and the tumor microenvironment and how these interactions promote tumor progression. Also, an outline of studies utilizing CCL20 in combination with other standard cancer treatments has been shed.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3285-3292"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.","authors":"Mohammad Taghizadeh-Teymorloei, Vahid Jafarlou, Somaieh Matin, Mortaza Raeisi, Yousef Roosta, Sima Mansouri-Derakhshani, Abbas Ali Hosseinpour Feizi, Abbas Karimi","doi":"10.1007/s12094-025-03863-8","DOIUrl":"10.1007/s12094-025-03863-8","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) remains a significant global health challenge, characterized by high morbidity and mortality rates. This study explores the potential of Alu-based cell-free DNA (cfDNA) and specific PIWI-interacting RNAs (piRNAs) as innovative biomarkers for monitoring treatment responses in CRC patients.</p><p><strong>Methods: </strong>We analyzed plasma samples from 70 CRC patients, equally divided between those undergoing chemotherapy and surgical interventions.</p><p><strong>Results: </strong>Our findings reveal that certain piRNAs, particularly piRNA-823, piRNA-54265, and piRNA-1245, exhibit significant prognostic value, with notable expression changes observed in the chemotherapy group compared to the surgery group. Furthermore, the levels of ALU-based cfDNA fragments showed a marked decrease post-chemotherapy, suggesting their utility in assessing therapeutic efficacy.</p><p><strong>Conclusions: </strong>This research underscores the importance of integrating these molecular tools particularly piRNA-823 and ALU-based cfDNA into clinical practice, potentially enhancing the management strategies for CRC patients and improving their outcomes.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3449-3457"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New evidence for miRNA testing in head and neck squamous cell cancer patients.","authors":"Blanca Pilar Galindo Torres, Raquel Alcaraz Ortega, Patricia Saiz López, María Isabel Adiego Leza, María Del Mar Moradillo Renuncio, Carlos García Girón, Miguel Víctor Grijalba Uche","doi":"10.1007/s12094-025-03854-9","DOIUrl":"10.1007/s12094-025-03854-9","url":null,"abstract":"<p><strong>Purpose: </strong>Prognosis of HNSCC has not changed over the last decades. MicroRNAs mediate gene expression and participate in regulating cellular biological processes. Its aberrant expression is an important event in the development of several cancers, including head and neck squamous cell cancer. The aim of the study is to determine if circulating miRNAs are reliable diagnostic indicators and can be used to monitor head and neck cancer.</p><p><strong>Methods/patients: </strong>An observational, longitudinal, prospective, analytical study was conducted, with a case-control design, in which 37 head and neck squamous cell cancer patients at diagnosis were compared with 30 healthy patients. Blood samples were obtained and free miRNA expression levels of 17 miRNAs were determined by PCR-RT. Follow-up of HNSCC was carried out for one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients.</p><p><strong>Results: </strong>Seventy-eight percent of the participants in HNSCC group and 57% among control group were men. Smokers and alcohol consumers exhibit increased susceptibility to HNSCC, and risk rises to 63.4% (R² = 0.634) when both factors are combined. HNSCC patients overexpressed miR-21-5p and miR-122, while miR-195-5p is downregulated. Elevated miR-21-5p levels correlates with tumour size and miR-374b-5p, with advanced stage (p = 0.005).</p><p><strong>Conclusion: </strong>Our findings suggest that the evaluation of certain miRNAs' expression levels in plasma can be used as potential markers for HNSCC diagnosis. Further assays with larger samples could be performed to validate data and establish a cut-off expression level for our proposed miRNAs.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3399-3409"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}